Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6742 multiple ascending dose study in systemic lupus erythematosus
jRCT2041210137Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of e6742 in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Safety and tolerability. Started Apr 2022; status: completed.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2041210137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210137.